Raynaud, digital ulcers and calcinosis in scleroderma;Raynaud, úlceras digitales y calcinosis en esclerodermia

Reumatologia Clinica

Volumn 8, Issue 5, 2012, Pages 270-277

  Nitsche, Alejandro ^a  

^a HOSPITAL ALEMÁN   (Argentina)

Author keywords

Calcinosis; Digital ulcers; Raynaud; Scleroderma

Indexed keywords

CALCINOSIS; CLINICAL FEATURE; FINGER ULCER; HAND FUNCTION; HOSPITALIZATION; HUMAN; RAYNAUD PHENOMENON; SCLERODERMA; SHORT SURVEY;

CALCINOSIS; CELL HYPOXIA; COMBINED MODALITY THERAPY; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; FINGERS; FOOT ULCER; HUMANS; ISCHEMIA; MULTICENTER STUDIES AS TOPIC; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC; SKIN ULCER; SULFONAMIDES; THROMBOPHILIA; THROMBOSIS; TOES; VASOCONSTRICTION; VASODILATOR AGENTS;

EID: 84865720189     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/j.reuma.2012.02.006     Document Type: Short Survey

References (68)

1. Hachulla E., Clerson P., Launay D., Lambert M., Morell-Dubois S., Queyrel V., et al. Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study. J Rheumatol 2007, 34:2423-2430.
2. Wigley F.M. Clinical practice. Raynaud's Phenomenon. N Engl J Med 2002, 347:1001-1008.
3. Sormani de Fonseca ML. Manual de capilaroscopía .Talleres Gráficos Alfa. Buenos Aires. Edición 2000.
4. Gross C.P., Mallory R., Heiat A., Krumholz H.M. Reporting the recruitment process in clinical trials: who are these patients and how did they get there?. Ann Inter Med 2002, 137:10-16.
5. Villela R., Yuen S.Y., Pope J.E., Baron M. Canadian Scleroderma Research Group. Assessment of unmet needs and the lack of generalizability in the design of randomized controlled trials for scleroderma treatment. Arthritis Rheum 2008, 59:706-713.
6. Herrick A.L. Contemporary management of Raynaud s phenomenon and digital ischaemic complications. Curr Opin Rheumatol 2011, 23:555-561.
7. Tingey T., Smucze J., Pope J. Treatment on healing and prevention of digital ulcers in systemic sclerosis (SSC): Results from a meta-analysis. Ann Rheum Dis 2011, 70(Suppl 3):484.
8. Steen V., Denton C.P., Pope J.E., Matucci-Cerinic M. Digital ulcers: overt vascular disease in systemic sclerosis. Rheumatology (Oxford) 2009, 4(Suppl 3):19-24.
9. Beltrán Catalán E., Román Ivorra J.A., Alegre Sancho J., Chalmeta Vedejo I., Fernández-Llanio Comella N., Ivorra Córtes J. úlceras digitales en esclerosis sistémica. Sem Fun Esp Reumatol 2008, 9:3-25.
10. Gabrielli A., Avvedimento E.V., Krieg T. Mechanisms of disease. Scleroderma. N Engl J Med 2009, 360:1989-2003.
11. Baltazares Lipp M., Rodríguez Crespo H., Ortega Martínez J., Sotres-Vega A., Baltazares Lipp M.E. Sistema endotelina. Rev Inst Nal Enf Resp Mex 2005, 18:308-320.
12. Spieker L.E., Noll G., Ruschitzka F.T., Lüscher T.F. Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future?. J Am Coll Cardiol 2001, 37:1493-1505.
13. Lüscher T.F., Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 2000, 102:2434-2440.
14. Yamane K., Miyauchi T., Suzuki N., Yuhara T., Akama T., Suzuki H., et al. Significance of plasma endothelin-1 levels in patients with systemic sclerosis. J Rheumatol 1992, 19:1566-1571.
15. Williams M.H., Das C., Handler C.E., Akram M.R., Davar J., Denton C.P., et al. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 2006, 92:926-932.
16. Amanzi L., Braschi F., Fiori G., Galluccio F., Miniati I., Giudicci S., et al. Digital ulcers in scleroderma: staging, characteristics and sub-setting through observation of 1614 lesions. Rheumatology 2010, 49:1374-1382.
17. Korn J.H., Mayes M., Matucci Cerinic M., Rainisio M., Pope J., Hachulla E., et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004, 50:3985-3993.
18. Matucci-Cerinic M., Denton C.P., Furst D.E., Mayes M.D., Hsu V.M., Carpentier P., et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2011, 70:32-38.
19. Doveri M., Della Rossa A., Salvadori S., D Ascanio A., Tavoni A., Bazzichi L., et al. Systemic sclerosis: outcome and long term follow-up of 429 pactients from a single Italian centre. Ann Rheum Dis 2011, 70(Suppl 3):660.
20. Boulman N., Slobodin G., Rozenbaum M., Rosner I. Calcinosis in rheumatic diseases. Semin Artritis Rheum 2005, 34:805-812.
21. Sulli A., Pizzorni C., Zampogna G. Transition from early to late pattern of nailfold microangiopathy in systemic sclerosis: a quick event to be strictly monitored. Ann Rheum Dis 2011, 70(Suppl 3):475.
22. Sulli A. Scoring the capillaroscopic images: which hallmark parameters should be scored. Ann Rheum Dis 2011, 70(Suppl 3):23.
23. Sebastiani M., Manfredi A., Vukatana G., Mosactelli S., Riato L., Bocci M., et al. Predictive role of capillaroscopic skin ulcer risk index in systemic sclerosis: a multicentre validation study. Ann Rheum Dis 2012, 71:67-70.
24. Avouac J., Fransen J., Walker U.A., Riccieri V., Smith V., Muller C., et al. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis 2011, 70:476-481.
25. Kowal-Bielecka O., Landewé R., Avouac J., Chwiesko S., Miniati I., Czirjak L., et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009, 68:620-628.
26. Fonollosa-Pla V., Simeón-Aznar C.P., Vilardell-Tarrés M. Tratamiento del fenómeno de Raynaud. Revista Clínica Española 2009, 209:21-24.
27. Rosato E., Molinaro I., Borghese F., Rossi C., Pisarri S., Salsano F. Bosentan improves skin perfusion of hands in patients with systemic sclerosis with pulmonary arterial hypertension. J Rheumatol 2010, 37:2531-2539.
28. Taniguchi T., Asano Y., Hatano M., Tamaki Z., Tomita M., Kawashima T., et al. Effects of bosentan on non digital ulcers in patients with systemic sclerosis. British J Dermatol 2012, 166:417-421.
29. Selenko-Gebauer N., Duschek N., Minimair G., Stingl G., Karlhofer F. Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan. Rheumatology (Oxford) 2006, 45(Suppl 3):iii45-iii48.
30. Hettema M.E., Zhang D., Bootsma H., Kallenberg C.G. Bosentan therapy for patients with severe Raynaud's phenomenon in systemic sclerosis. Ann Rheum Dis 2007, 66:1398-1399.
31. Ramos-Casals M., Brito-Zerón P., Nardi N., Claver G., Risco G., Parraga F.D., et al. Successful treatment of severe Raynaud's phenomenon with bosentan in four patients with systemic sclerosis. Rheumatology (Oxford) 2004, 43:1454-1456.
32. Dunne J., Dutz J., Shojania K., Ng B., Van Eeden S. Treatment of severe Raynaud's phenomenon with bosentan in a patient with systemic sclerosis. Rheumatology (Oxford) 2006, 45:911-912.
33. Seibold J.R., Matucci-Cerinic M., Denton C.P., Furst D.E., Mayes M.D., Kramer F., et al. Bosentan reduces the number of new digital ulcers in patients with systemic sclerosis. Ann Rheum Dis 2006, 65(Suppl II):90.
34. García de la Peña-Lefebvre P., Rodríguez Rubio S., Valero Expósito M., Carmona L., Gámir Gámir M.L., Beltrán Gutiérrez J., et al. Long-term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients. Rheumatology (Oxford) 2008, 47:464-466.
35. Launay D., Diot E., Pasquier E., Mouthon L., Boullanger N., Fain O., et al. Bosentan for treatment of active digital ulcers in patients with systemic sclerosis. Presse Med 2006, 35(4 Pt 1):587-592.
36. Moore T.L., Vail A., Herrick A.L. Assessment of digital vascular structure and function in response to bosentan in patients with systemic sclerosis-related Raynaud's phenomenon. Rheumatology (Oxford) 2007, 46:363-364.
37. Sfikakis P.P., Papamichael C., Stamatelopoulos K.S., Tousoulis D., Fragiadaki K.G., Katsichti P., et al. Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis. Arthritis Rheum 2007, 56:1985-1993.
38. Denton C.P., Howell K., Stratton R.J., Black C.M. Long term low molecular weight heparin therapy for severe Raynaud s phenomenon: a pilot study. Clin Exp Rheumatol 2000, 18:499-502.
39. Roman Ivorra J.A., Simeon C.P., Alegre Sancho J.J., Egurbide M.V., Castillo M.J., Lloria X., et al. Bosentan in clinical practice for treating digital and other ischemic ulcers in spanish patients with systemic sclerosis: IBER-DU cohort study. J Rheumatol 2011, 38:1631-1635.
40. Kuhn A., Haust M., Ruland V., Weber R., Verde P., Felder G., et al. Effect of bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, open-label, non-comparative trial. Rheumatology (Oxford) 2010, 49:1336-1345.
41. Funauchi M., Kishimoto K., Shimazu H., Nagare Y., Hino S., Yano T., et al. Effects of bosentan on the skin lesions: an observational study from a single center in Japan. Rheumatol Int 2009, 29:769-775.
42. Thompson A.E., Pope J.E. Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis. Rheumatology (Oxford) 2005, 44:145-150.
43. Vinjar B., Stewart M. Oral vasodilators for primary Raynaud's phenomenon. Cochrane Database Syst Rev 2008, 16:CD006687.
44. Dziadzio M., Denton C.P., Smith R., Howell K., Blann A., Bowers E., et al. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 1999, 42:2646-2655.
45. Franks A.G Topical glyceryl trinitrate as adjunctive treatment in Raynaud's disease. Lancet 1982, 1:76-77.
46. Teh L.S., Manning J., Moore T., Tully M.P., O'Reilly D., Jayson M.I. Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon. Br J Rheumatol 1995, 34:636-641.
47. Caglayan E., Huntgeburth M., Karasch T., Weihrauch J., Hunzelmann N., Krieg T., et al. Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease. Arch Intern Med 2006, 166:231-233.
48. Kumar N., Griffiths B., Allen J. Thermographic and symptomatic effect of a single dose of sildenafil citrate on Raynaud's phenomenon in patients with systemic sclerosis: a potential treatment. J Rheumatol 2006, 33:1918-1919.
49. Brueckner C.S., Becker M.O., Kroencke T., Huscher D., Scherer H.U., Worm M., et al. Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study. Ann Rheum Dis 2010, 69:1475-1478.
50. De LaVega A.J., Derk C.T. Phosphodiesrerase-5 inhibitors for the treatment of Raynauds: a novel indication. Expert Opin Investig Drugs 2009, 18:23-29.
51. García Hernández F.J., Ocaña Medina C., Mateos Romero L., Molinillo López J., Arias Zambrano A., González León R., et al. Iloprost for severe Raynaud's phenomenon and ischaemic ulcers related with systemic diseases. Med Clin (Barc) 2004, 122:501-504.
52. Engel E., Rockson S. Treprostinil for the treatment of severe digital necrosis in systemic sclerosis. Vascular Medicine 2005, 10:29-32.
53. Beltrán E., Pérez García C., Blanch J., Toll A., Segales N., Prado I., et al. Treatment of severe Raynaud's phenomenon in collagen diseases with alprostadil IV. Ann Rheum Dis 2005, 64(Suppl III):S304.
54. Rajagopalan S., Pfenninger D., Somers E., Kehrer C., Chakrabarti A., Mukherjee D., et al. Effects of cilostazol in patients with Raynauds syndrome. Am J Cardiol 2003, 92:1310-1315.
55. Rey J., Cretel E., Jean R., Pastor M.J., Durand J.M. Serotonin reuptake inhibitors, Raynaud's phenomenon and erythromelalgia. Rheumatology 2003, 42:601-602.
56. Buecking A., Rougemont E., Zullino D.F. Treatment of Raynaud's phenomenon with escitalopram. Int J Neuropsychopharmacol 2005, 8:307-308.
57. Coleiro B., Marshall S.E. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology 2001, 40:1038-1043.
58. Bell C., Coupland N., Creamer P. Digital infarction in a patient with Raynaud's phenomenon associated with treatment with a specific serotonin reuptake inhibitor. A case report. Angiology 1996, 47:901-903.
59. Peiró A.M., Margarit C., Torra M. Citalopram-induced Raynaud's phenomenon. Rheumatol Int 2007, 27:599-601.
60. Sambo P., Amico D., Giacomelli R., Matucci-Cerinic M., Salsano F., Valentini G., et al. Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: a pilot study. J Rheumatol 2001, 28:2257-2262.
61. Salsano F., Letizia C., Proietti M., Rossi C., Proietti A.R., Rosato E., et al. Significant changes of peripheral perfusion and plasma adrenomedullin levels in N-acetylcysteine long term treatment of patients with sclerodermic Raynaud's phenomenon. Int J Immunopathol Pharmacol 2005, 18:761-770.
62. Abou-Raya A., Abou-Raya S., Helmii M. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers. J Rheumatol 2008, 35:1801-1808.
63. Fregene A., Ditmars D., Siddiqui A. Botulinum toxin type A: a treatment option for digital ischemia in patients with Raynaud's phenomenon. J Hand Surg 2009, 34A:446-452.
64. Fiori G., Galluccio F., Braschi F., Amanzi L., Miniati I., Conforti M.L., et al. Vitamin E gel reduces time of healing of digital ulcers in systemic sclerosis. Clin Exp Rheumatol 2009, 27(3 Suppl 54):51-54.
65. Kotsis S.V., Chung K.C. A systematic review of the outcomes of digital sympathectomy for treatment of chronic digital ischemia. J Rheumatol 2003, 30:1788-1792.
66. Coveliers H.M., Hoexum F., Nederhoed J.H., Wisselink W., Rauwerda J.A. Thoracic sympathectomy for digital ischemia: a summary of evidence. J Vasc Surg 2011, 54:273-277.
67. Balin S.J., Wetter D.A., Andersen L.K., Davis M.D. Calcinosis cutis occurring in association with autoimmune connective tissue disease. The Mayo Clinic Experience with 78 patients, 1996-2009. Arch Dermatol 2012, 184:455-462.
68. Daoussis D., Antonopoulos I., Liossis S.N., Yiannopoulos G., Andonopoulos A.P. Treatment of systemic sclerosis-associated calcinosis: a case report of rituximab-induced regression of CREST-related calcinosis and review of the literature. Semin Arthritis Rheum 2012, 41:822-829.